Global Hyaluronidase Market is expected to reach USD 1,326.9 million by 2030

The global hyaluronidase market size was valued at USD 863.12 Million in 2022 and is expected to reach USD 1,326.9 Million by 2030, growing at a compound annual growth rate (CAGR) of 9.01% during the forecast period.

Hyaluronidase is an enzyme that breaks down hyaluronic acid, a natural substance found in the body's connective tissues. It is a versatile enzyme that is used in various medical and cosmetic applications. The enzyme is primarily used as an adjuvant in anesthesia and to improve the absorption and dispersion of drugs. It is also used in the treatment of medical conditions such as cancer, ophthalmology, and in surgical procedures. In the cosmetic industry, hyaluronidase is used to reduce swelling and bruising associated with injectable fillers and to reverse the effects of overfilling.

Hyaluronidase is generally well-tolerated, but some patients may experience adverse effects such as allergic reactions, including anaphylaxis. As a result, it should be used with caution, and patients should be monitored closely for any adverse reactions. The regulatory landscape for hyaluronidase varies across countries, and some countries have strict regulations regarding its use. Thus, hyaluronidase has proven to be a useful enzyme in various applications, and ongoing research is likely to uncover even more uses for this versatile enzyme.

The global hyaluronidase market is driven by several factors, including the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, and growing awareness of hyaluronidase applications in the pharmaceutical & cosmetic industries. Technological advancements in drug delivery systems and the availability of funding for research & development activities are creating new opportunities for the market. However, the market also faces challenges such as the high cost of treatment, adverse side effects, and strict regulations regarding the use of hyaluronidase. The limited availability of skilled professionals trained in administering hyaluronidase and the risk of infections associated with its use may also pose challenges. Despite these restraints, the increasing adoption of hyaluronidase in developing countries and the development of biosimilars are expected to create new growth opportunities for the market in the future.

The global hyaluronidase market is segmented into type, application, and region.

Based on type, the market is bifurcated into animal-derived hyaluronidase and synthetic hyaluronidase. The animal-derived hyaluronidase segment held the largest market share in 2022 and is further predicted to cite a notable CAGR during the forecast period. The animal-derived hyaluronidase segment of the market is expected to experience steady growth due to the increasing demand for hyaluronidase in animal husbandry and veterinary medicine. Animal-derived hyaluronidase is commonly used to improve the effectiveness of vaccines, particularly in poultry and swine industries, and as a wound-healing agent in veterinary medicine. In addition, animal-derived hyaluronidase is used in various research and development activities in the pharmaceutical and biotechnology industries. The animal-derived hyaluronidase segment is also expected to benefit from the growing trend toward the use of natural and organic products in the cosmetic industry. Animal-derived hyaluronidase is used as an ingredient in skincare products, particularly in anti-aging products, due to its ability to stimulate collagen production and improve skin hydration.

Based on application, the hyaluronidase industry is segmented into chemotherapy, dermatology, ophthalmology, plastic surgery, and others. The dermatology segment held a dominating market share in 2022 and is further projected to cite a notable CAGR during the forecast period. The dermatology segment of the hyaluronidase market is expected to experience significant growth due to the rising demand for injectable dermal fillers and the increasing popularity of minimally invasive cosmetic procedures.

Hyaluronidase is used in dermatology to quickly dissolve hyaluronic acid-based dermal fillers, which are commonly used to treat wrinkles, fine lines, and volume loss. The increasing prevalence of skin-related conditions, such as acne and rosacea, is also expected to drive the demand for hyaluronidase in dermatology. Hyaluronidase is used as a treatment for these conditions, as it can help to reduce inflammation and promote wound healing. The dermatology segment is expected to benefit from the growing trend toward natural and organic skincare products. Hyaluronidase is increasingly being used as an ingredient in these products, as it has been shown to stimulate collagen production and improve skin hydration.

Based on region, the North American region held the largest hyaluronidase market share in 2022 and is further predicted to grow rapidly at a significant CAGR during the forecast period. This is mainly due to the increasing demand for hyaluronidase in various medical and cosmetic applications. The rising prevalence of skin-related conditions such as acne, rosacea, and wrinkles has resulted in the increased adoption of hyaluronidase in dermatology. Moreover, the growing geriatric population in North America is also expected to drive the demand for hyaluronidase, particularly in the treatment of age-related conditions such as osteoarthritis. The increasing prevalence of chronic diseases such as cancer and diabetes is also expected to boost the demand for hyaluronidase as an adjuvant therapy to improve drug delivery. North America is a prominent market for cosmetic procedures, and hyaluronidase is increasingly being used as a treatment for overfilled areas or unwanted lumps resulting from dermal filler injections. The availability of advanced healthcare infrastructure, higher disposable income, and the presence of key market players in the region are some of the factors contributing to the growth of the hyaluronidase market in North America.

This review is based on a report by Zion Market Research, titled “Hyaluronidase Market By Type (Animal-Derived Hyaluronidase and Synthetic Hyaluronidase), By Application (Chemotherapy, Dermatology, Ophthalmology, Plastic Surgery, and Others), and By Region: Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts, 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/hyaluronidase-market

Recent Developments

• In August 2021, Halozyme Therapeutics, Inc. announced the initiation of Phase 3 clinical trial for its investigational drug, PEGPH20, in combination with chemotherapy in patients with previously untreated metastatic pancreatic cancer. PEGPH20 is a pegylated recombinant human hyaluronidase that targets the extracellular matrix of tumors to improve the delivery of chemotherapy.
• In July 2021, Shire, a subsidiary of Takeda Pharmaceutical Company Limited, received FDA approval for its investigational enzyme replacement therapy, HyQvia, for the treatment of primary immunodeficiency. HyQvia contains recombinant human hyaluronidase and is administered subcutaneously to improve the absorption and distribution of immunoglobulin.
• In June 2021, Abbott announced the launch of its Alinity m system, a molecular diagnostic instrument that offers a broad range of infectious disease testing capabilities. The instrument features the company's proprietary hyaluronidase pretreatment technology, which is designed to enhance the extraction of DNA and RNA from samples.

The global hyaluronidase market is dominated by players such as:

• Baxter International Inc.
• Halozyme Therapeutics Inc.
• Pfizer Inc.
• Shire Plc
• F. Hoffmann-La Roche Ltd.
• Sandoz International GmbH
• Quidel Corporation
• CSL Limited
• Pharming Group NV
• IBSA Institut Biochimique SA
• Fresenius Kabi AG
• Johnson & Johnson
• Nordic Group BV
• Bausch Health Companies Inc.
• AstraZeneca
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Santen Pharmaceutical Co. Ltd.
• Sanofi SA.

Global Hyaluronidase Market is segmented based on:

By Type

• Animal-Derived Hyaluronidase
• Synthetic Hyaluronidase

By Application

• Chemotherapy
• Dermatology
• Ophthalmology
• Plastic Surgery

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com